The results of splenectomy for hematologic disorders in 200 patients have been evaluated. Anticipated good results were achieved in all patients with hereditary spherocytosis and over 80% of patients with idiopathic thrombocytopenic purpura. A hematologic improvement in patients with thrombotic thrombocytopenic purpura, thalassemia, myeloid metaplasia, and malignant hemopathy occurred in a significant percentage of cases. The overall in-hospital mortality was 7% but was totally related to the primary disease process. It was concluded that the results justify broadening the indications for splenectomy in patients with hematologic disorders.
Schwartz SI, Bernard RP, Adams JT, Bauman AW. Splenectomy for Hematologic Disorders. Arch Surg. 1970;101(2):338–347. doi:10.1001/archsurg.1970.01340260242036
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.